S
Savara Inc. (SVRA)
NMS – Real vaqt narxi. Valyuta: USD
5.08
-0.04 (-0.78%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
5.08
-0.04 (-0.78%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Savara Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda kam uchraydigan respirator kasalliklarga e'tibor qaratadi. Kompaniyaning asosiy mahsulot nomzodi molgramostim, inhalatsiyalangan granulotsit-makrofag koloniya-stimulyatsiya qiluvchi omil bo'lib, u autoimmun o'pka alveolyar proteinosisini davolash uchun 3-bosqichli rivojlanish bosqichida. Savara Inc. 2007 yilda tashkil etilgan va uning shtab-kvartirasi Pensilvaniya shtatining Langhorn shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Brian Maurer | Head of Clinical Operations |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs |
| Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations |
| Dr. Yasmine Wasfi M.D., Ph.D. | Chief Medical Officer |
| Mr. Charles LaPree | Executive VP & Head of Global Regulatory Affairs |
| Mr. David L. Lowrance CPA | Chief Financial & Administrative Officer and Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | svra-20260331.htm |
| 2026-04-24 | DEFA14A | d12714ddefa14a.htm |
| 2026-04-24 | ARS | d57226dars.pdf |
| 2026-04-10 | PRE 14A | d11872dpre14a.htm |
| 2026-03-13 | 8-K | d107834d8k.htm |
| 2026-01-27 | 8-K | d39349d8k.htm |
| 2026-01-09 | 8-K | d24211d8k.htm |
| 2025-11-12 | 10-Q | svra-20250930.htm |
| 2025-09-02 | 8-K | d12513d8k.htm |
| 2025-08-13 | 10-Q | svra-20250630.htm |
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO |
| Mr. Robert Matthew Lutz M.B.A. | Chief Operating Officer |
| Ms. Anne Erickson | Chief Business & Corporate Affairs Officer |
| Ms. Kate McCabe J.D. | Chief Legal Officer |